News

Press Release: OSEL Begins Phase 2/3 Clinical study for prevention of AAD
SANTA CLARA, October 11 /PRNewswire/-- Osel Inc., the Bacterio-Therapeutics Company, has enrolled the first subjects into its Phase 2/3 clinical study for the prevention of Antibiotic Associated Diarrhea (AAD). Download full article
Press Release: Osel receives NIH award under partnerships for topical microbicides
SANTA CLARA, June 9, 2005 /PRNewswire/-- Osel, Inc., the Bacterio-Therapeutics company, announced award of a multiple-year grant from the NIAID, NIH towards development of an encapsulated MucoCept Lactobacillus strain for therapeutic prevention of bacterial vaginosis (BV) and HIV infection under support of the Partnerships for Topical Microbicides... Download full article
Press Release: Osel initiates two Phase-II trials for LACTIN-V
SANTA CLARA, April 12, 2005 /PRNewswire/-- Osel, Inc., the Bacterio-Therapeutics company, announced the initiation of two Phase II clinical trials of LACTIN-V, one for the treatment of recurrent urinary tract infection (RUTI), and a second for recurrent bacterial vaginosis (RBV)... Download full article
Press Release: Osel in-licenses therapeutic drug product from Japan 3/2/05
SANTA CLARA, March 2, 2005 /PRNewswire/-- Osel, Inc., the Bacterio-Therapeutics company, has signed a definitive in-licensing agreement for MIYA-BM®, an oral therapeutic drug product from Miyarisan Pharmaceutical Company, Ltd. of Japan. Osel has exclusive rights to commercialize the product in North America and Europe... Download full article
Press Release: Osel Announces Private Funding Round 12/2004 - PDF
SANTA CLARA, December 21, 2004 /PRNewswire/-- Osel, Inc., the Bacterio-Therapeutics company, closed a private round of financing, completed the in-clinic portion of a Phase I clinical trial for their first product, LACTIN-V, for the treatment of recurrent bacterial vaginosis, and announced the appointment of Michael Cannon as a new board member... Download full article